SPRY
ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc historical holders
total: 1
Third Point ARS Pharmaceuticals, Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Added:
- 1
- Held since:
- 2025 Q4
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q1
Daniel Loeb has been an institutional investor in ARS Pharmaceuticals, Inc (SPRY) since 2025 Q4. According to 2026 Q1 report, Daniel Loeb holds 1,000,000 shares with a market value of roughly $8.03M representing 0.39% of their equity portfolio. The fund/company first acquired SPRY in 2025 Q4, initially purchasing 556,237 shares. Since the initial investment, Third Point has made 1 more transaction in this position.
Does Daniel Loeb still hold SPRY?
Yes, Daniel Loeb continues to hold ARS Pharmaceuticals, Inc (SPRY). According to their 2026 Q1 report, they maintain a position of 1,000,000 shares valued at approximately $8.03M, representing 0.39% of their equity portfolio.
When did Daniel Loeb first invest in SPRY?
Daniel Loeb first invested in ARS Pharmaceuticals, Inc (SPRY) in 2025 Q4 at the reported quarter-end price of $11.65 per share, acquiring 556,237 shares in their initial purchase.
What is Daniel Loeb's average cost basis for SPRY?
Based on historical transaction data, Daniel Loeb's estimated cost basis for ARS Pharmaceuticals, Inc (SPRY) is approximately $10.04 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $10.04
SPRY transactions history by Third Point
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.39%
|
1,000,000
|
$8.03
|
$8,030,000
|
+79.78% (+443,763)
|
+0.17%
|
|
2025 Q4
|
0.09%
|
556,237
|
$11.65
|
$6,480,161
|
new
|
+0.09%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.